eligibility_summary
Adults ≥18 with histologic GBM/astrocytoma G4 (new or 1st recurrence ≥12 wks post‑RT), CMV+, ECOG 0–1, ≥6‑mo life, adequate organs, tissue available, HLA‑matched CMV T cells, consent, contraception. HBV/HCV ok if suppressed. Exclude: prior checkpoint inhibitor, recent therapy/device or live vaccine, immunodeficiency/ >10 mg steroids, active autoimmunity, pneumonitis or infection, HIV, active HBV/HCV, transplant, QTc>450 ms, pregnant/breastfeeding. Newly dx must delay adjuvant temozolomide.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Interventions: 1) Allogeneic cytomegalovirus (CMV)-specific T cells (CYT-101) — biological, adoptive T‑cell therapy derived from healthy CMV‑seropositive donors, HLA-matched CMV‑specific T cells aim to recognize CMV antigens presented by glioblastoma cells and kill them via T‑cell cytotoxicity and cytokine release. 2) Pembrolizumab (Keytruda) — drug, humanized IgG4 monoclonal antibody checkpoint inhibitor against PD‑1, blocks PD‑1 on T cells to reverse exhaustion and amplify antitumor immunity. Targets/pathways: CMV antigen–presenting tumor cells, TCR recognition of CMV peptides on HLA, PD‑1/PD‑L1 inhibitory pathway in the tumor microenvironment. Trial tests CMV‑specific T cells as monotherapy or combined with pembrolizumab in recurrent or newly diagnosed GBM/grade 4 astrocytoma.